Victoria M Rimkunas

US Patent:

20120093837, Apr 19, 2012

Filed:

Apr 10, 2009

Appl. No.:

12/450457

Inventors:

Jiong Wu - Reading MA, US
Susan Kane - Beverly MA, US
Jian Yu - Hamilton MA, US
Herbert Haack - South Hamilton MA, US
James Wieler - Exeter NH, US
Jun-Ming Cai - South Hamilton MA, US
Victoria Rimkunas - Somerville MA, US

International Classification:

A61K 39/395
C12N 15/13
A61P 35/00
G01N 33/574
G01N 21/64
A61K 31/7088
C07K 16/28
C12N 15/63

US Classification:

4241741, 5303898, 53038822, 5303879, 536 2353, 4353201, 435 723, 514 44 R

Abstract:

The invention discloses binding agents to the E746-A750 deletion and the L858R point mutations in the epidermal growth factor receptor (EGFR) molecule, and methods for use thereof, including methods for the diagnosis and treatment of cancer.

US Patent:

20120101108, Apr 26, 2012

Filed:

Aug 5, 2011

Appl. No.:

13/204342

Inventors:

Herbert Haack - South Hamilton MA, US
Katherine Eleanor Crosby - Middleton MA, US
Victoria McGuinness Rimkunas - Reading MA, US
Matthew Ren Silver - Rockport MA, US

Assignee:

CELL SIGNALING TECHNOLOGY, INC. - Danvers MA

International Classification:

A61K 31/496
A61K 31/4545
C12Q 1/48
C12Q 1/68
G01N 33/573

US Classification:

51425218, 435 611, 435 612, 435 614, 435 618, 435 74, 435 15, 514318

Abstract:

The invention provides methods to identify, diagnose, and treat kidney cancer through the detection of expression and/or activity of anaplastic lymphoma kinase (ALK). The detection of the presence of a polypeptide with ALK kinase activity (e.g., by detecting expression and/or activity of the polypeptide), identify those kidney cancers that are likely to respond to an ALK-inhibiting therapeutic.

US Patent:

20120208824, Aug 16, 2012

Filed:

May 23, 2011

Appl. No.:

13/113676

Inventors:

Victoria McGuinness Rimkunas - Reading MA, US
Herbert Haack - South Hamilton MA, US
Ailan Guo - Lexington MA, US
Anthony Paul Possemato - Worcester MA, US
Katherine Eleanor Crosby - Middleton MA, US
Meghan Ann Tucker - Salem MA, US
Cynthia Reeves - Beverly MA, US

Assignee:

Cell Signaling Technology, Inc. - Danvers MA

International Classification:

A61K 31/4545
A61K 31/506
G01N 33/574
G01N 33/53
C12Q 1/68
A61P 35/00
G01N 33/573

US Classification:

51425218, 514318, 435 74, 435 611, 435 618, 435 612

Abstract:

The invention provides the identification of the presence of polypeptides with ROS kinase activity in mammalian lung cancer. In some embodiments, the polypeptide with ROS kinase activity is the result of a fusion between a ROS-encoding polynucleotide and a polynucleotide encoding a second (non-ROS) polypeptide. Three different fusion partners of ROS are described, namely proteins encoded by the FIG gene, the SLC34A2 gene, and the CD74 gene. The invention enables new methods for determining the presence of a polypeptide with ROS kinase activity in a biological sample, methods for screening for compounds that inhibit the proteins, and methods for inhibiting the progression of a cancer (e.g., an lung cancer).

US Patent:

20130288240, Oct 31, 2013

Filed:

May 23, 2011

Appl. No.:

13/699309

Inventors:

Victoria McGuinness Rimkunas - Reading MA, US
Herbert Haack - South Hamilton MA, US
Katherine Eleanor Crosby - Middleton MA, US
Nancy Chiu Wilker - Lexington MA, US

Assignee:

CELL SIGNALING TECHNOLOGY, INC. - Danvers MA

International Classification:

C12Q 1/68
C12Q 1/48

US Classification:

435 611, 435 612, 435 74

Abstract:

A method for identifying a patient with cancer or suspected of having cancer as a patient likely to respond to an ALK- and/or ROS-inhibiting therapeutic is provided, the method comprising: contacting a biological sample from a patient with a first reagent that specifically binds a polypeptide having ROS kinase activity and a second reagent that specifically binds to a polypeptide having ALK kinase activity, and detecting whether the first reagent or the second reagent specifically binds to the biological sample, wherein detection of binding of either the first reagent or the second reagent to the biological sample identifies the patient as a patient likely to respond to an ALK-inhibiting and/or ROS-inhibiting therapeutic.

US Patent:

20110287445, Nov 24, 2011

Filed:

Feb 12, 2010

Appl. No.:

13/146705

Inventors:

Meghan Ann Tucker - Salem MA, US
Herbert Haack - South Hamilton MA, US
Katherine Eleanor Crosby - Middleton MA, US
Victoria McGuinness Rimkunas - Somerville MA, US

Assignee:

CELL SIGNALING TECHNOLOGY, INC. - Danvers MA

International Classification:

G01N 33/573
G01N 33/566
C07H 21/04
C07H 21/00
C07K 2/00
C12N 9/12
C07K 16/40

US Classification:

435 71, 435194, 436501, 5303891, 536 2431, 530300, 5303879, 536 232

Abstract:

The invention provides the identification of the presence of mutant ROS protein in human cancer. In some embodiments, the mutant ROS are FIG-ROS fusion proteins comprising part of the FIG protein fused to the kinase domain of the ROS kinase. In some embodiments, the mutant ROS is the overexpression of wild-type ROS in cancerous tissues (or tissues suspected of being cancerous) where, in normal tissue of that same tissue type, ROS is not expressed or is expressed at lower levels. The mutant ROS proteins of the invention are anticipated to drive the proliferation and survival of a subgroup of human cancers, particularly in cancers of the liver (including bile duct), pancreas, kidney, and testes. The invention therefore provides, in part, isolated polynucleotides and vectors encoding the disclosed mutant ROS polypeptides (e.g., a FIG-ROS(S) fusion polypeptide), probes for detecting it, isolated mutant polypeptides, recombinant polypeptides, and reagents for detecting the fusion and truncated polypeptides. The identification of the mutant ROS polypeptides enables new methods for determining the presence of these mutant ROS polypeptides in a biological sample, methods for screening for compounds that inhibit the proteins, and methods for inhibiting the progression of a cancer characterized by the mutant polynucleotides or polypeptides, which are also provided by the invention.

US Patent:

20220267854, Aug 25, 2022

Filed:

Oct 13, 2021

Appl. No.:

17/500122

Inventors:

- Danvers MA, US
Victoria MCGUINNESS RIMKUNAS - Reading MA, US
Matthew Ren SILVER - Rockport MA, US
Herbert HAACK - South Hamilton MA, US

Assignee:

CELL SIGNALING TECHNOLOGY, INC. - Danvers MA

International Classification:

C12Q 1/6886
C12N 9/12
C07K 14/71
C07K 14/74
G01N 33/574
C07K 14/705
A61K 31/4545
A61K 31/506

Abstract:

The present disclosure provides methods of that include detecting in a biological sample from a patient having or suspected of having cancer the presence of a polypeptide having ROS1 kinase activity or a polynucleotide encoding the same and detecting in the biological sample the presence of a mutant EGFR polypeptide or a polynucleotide encoding the same. In some aspects, the disclosure provides methods of treating a patient tor cancer that include determining that a biological sample from a tumor in the patient includes a polypeptide having ROS1 kinase activity or a polynucleotide encoding the same and a mutant EGFR polypeptide or a polynucleotide encoding the same and administering to the patient a therapeutically effective amount of a ROS1 inhibitor and an EGFR inhibitor, thereby treating the patient for cancer.

US Patent:

20220226300, Jul 21, 2022

Filed:

May 15, 2020

Appl. No.:

17/613681

Inventors:

- Bunkyo-ku, Tokyo, JP
Nathalie M. RIOUX - Woburn MA, US
Victoria RIMKUNAS - Reading MA, US

Assignee:

Eisai R&D Management Co., Ltd. - Bunkyo-ku, Tokyo

International Classification:

A61K 31/4439
A61P 35/00
A61K 9/48

Abstract:

The present invention relates to pharmaceutical compositions comprising an inhibitor of human ERα, and methods of cancer therapy using the ERα inhibitor. In particular, described herein are dosages of H3B-6545 with defined pharmacokinetic (PK) profiles that allow the inhibitor to be efficaciously and safely administered to a human subject in need thereof.

US Patent:

20200363417, Nov 19, 2020

Filed:

Dec 30, 2019

Appl. No.:

16/729736

Inventors:

- Danvers MA, US
Katherine Eleanor Crosby - Middleton MA, US
Victoria McGuinness Rimkunas - Reading MA, US
Matthew Ren Silver - Rockport MA, US

Assignee:

Cell Signaling Technology, Inc. - Danvers MA

International Classification:

G01N 33/574
A61K 31/4162
A61K 31/4545
A61K 31/517
C12Q 1/6886

Abstract:

The invention provides methods to identify, diagnose, and treat kidney cancer through the detection of expression and/or activity of anaplastic lymphoma kinase (ALK). The detection of the presence of a polypeptide with ALK kinase activity (e.g., by detecting expression and/or activity of the polypeptide), identify those kidney cancers that are likely to respond to an ALK-inhibiting therapeutic.